Associate Professor

Colm Keane

Email: 
Phone: 
+61 7 344 37912

Background

Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.

Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.

Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.

The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.

Availability

Associate Professor Colm Keane is:
Available for supervision

Qualifications

  • Masters (Coursework) of Business Administration, Griffith University
  • Doctor of Philosophy, Griffith University

Research interests

  • Tumour Immunology

  • DLBCL

  • Primary CNS Lymphoma

  • Hodgkin Lymphoma

  • Viral Associated Lymphomas

Search Professor Colm Keane’s works on UQ eSpace

129 works between 2004 and 2025
All (129) Journal Article (69) Book Chapter (1) Conference Publication (59)

81 - 100 of 129 works

2018

Journal Article

Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

Vari, Frank, Arpon, David, Keane, Colm, Hertzberg, Mark S, Talaulikar, Dipti, Jain, Sanjiv, Cui, Qingyan, Han, Erica, Tobin, Josh, Bird, Robert, Cross, Donna, Hernandez, Annette, Gould, Clare, Birch, Simone and Gandhi, Maher K (2018). Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood, 131 (16), 1809-1819. doi: 10.1182/blood-2017-07-796342

Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

2018

Conference Publication

Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

Keane, Colm, Law, Soi C., Gould, Clare, Francis, Santiyagu, Abro, Emad Uddin, Tobin, Joshua W. D., Birch, Simone, Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Talaulikar, Dipti, Gill, Anthony, Jain, Sanjiv, Cross, Donna, Hernadez, Annette, Halliday, Sarah-Jane, Bird, Robert, Hertzberg, Mark and Gandhi, Maher K. (2018). Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, 1-4 December 2018. Washington, DC, Untied States: American Society of Hematology. doi: 10.1182/blood-2018-99-112830

Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

2018

Conference Publication

The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma

Gunawardana, Jay, Bednarska, Karolina, Law, Soi C., Lee, Justina, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Birch, Simone, Keane, Colm and Gandhi, Maher K. (2018). The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego CA, United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-115836

The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma

2018

Journal Article

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity

McKee, Sara J., Tuong, Zewen K., Kobayashi, Takumi, Doff, Brianna L., Soon, Megan S. F ., Nissen, Michael, Lam, Pui Yeng, Keane, Colm, Vari, Frank, Moi, Davide, Mazzieri, Roberta, Leggatt, Graham, Gandhi, Maher K. and Mattarollo, Stephen R. (2018). B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology, 7 (2) e1393599, e1393599. doi: 10.1080/2162402X.2017.1393599

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity

2018

Conference Publication

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

2017

Conference Publication

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

Tobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh, Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

2017

Journal Article

Stem cell-based therapies for sepsis

Keane, Colm, Jerkic, Mirjana and Laffey, John G. (2017). Stem cell-based therapies for sepsis. Anesthesiology, 127 (6), 1017-1034. doi: 10.1097/ALN.0000000000001882

Stem cell-based therapies for sepsis

2017

Journal Article

The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma

Keane, Colm, Gould, Clare, Jones, Kimberley, Hamm, David, Talaulikar, Dipti, Ellis, Jonathan, Vari, Frank, Birch, Simone, Han, Erica, Wood, Peter, Le-Cao, Kim-Anh, Green, Michael R., Crooks, Pauline, Jain, Sanjiv, Tobin, Josh, Steptoe, Raymond J. and Gandhi, Maher K. (2017). The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma. Clinical Cancer Research, 23 (7), 1820-1828. doi: 10.1158/1078-0432.CCR-16-1576

The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma

2017

Conference Publication

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Tobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

2017

Conference Publication

The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD

Gandhi, Maher K., Keane, Colm, Tobin, Joshua W. D., Talaulikar, Dipti, Jain, Sanjiv, Vari, Frank, Kruze, Lutz, Murigneux, Valentine, Fink, Lynn, Gunawardana, Jithendra, Gould, Clare, Oey, Harold, Fink, Susanne, Trappe, Ralf Ulrich, Mathews, Marina, Francis, Santiyagu and Hoang, Thanh (2017). The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA, United States, 9-12 December 2017. Washington, DC, United States: American Society of Hematology.

The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD

2017

Conference Publication

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Shanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

2016

Journal Article

The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

Jones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016). The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 (2), 206-220. doi: 10.1111/cei.12716

The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

2016

Conference Publication

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

Gandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology.

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

2015

Journal Article

Copy-number variation and false positive results of prenatal screening

Kingsley, Christopher, Wang, Eric, Oliphant, Arnold, Van Den Boom, Dirk, Ehrich, Mathias, Kim, Sung K., Jivan, Yatika, Peach, Betsy, Keane, Colm, Snyder, Matthew W., Gammill, Hilary S. and Shendure, Jay (2015). Copy-number variation and false positive results of prenatal screening. New England Journal of Medicine, 373 (26), 2583-2585. doi: 10.1056/NEJMc1507106

Copy-number variation and false positive results of prenatal screening

2015

Journal Article

Copy-number variation and false positive results of prenatal screening

Jivan, Yatika, Peach, Betsy and Keane, Colm (2015). Copy-number variation and false positive results of prenatal screening. The New England Journal of Medicine, 373 (26), 2584-2585. doi: 10.1056/NEJMc1507106

Copy-number variation and false positive results of prenatal screening

2015

Journal Article

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

Keane, Colm, Vari, Frank, Hertzberg, Mark, Le Cao, Kim-Anh, Green, Michael R., Han, Erica, Seymour, John F., Hicks, Rodney J., Gill, Devinder, Crooks, Pauline, Gould, Clare, Jones, Kimberley, Griffiths, Lyn R., Talaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, 2 (10), e445-e455. doi: 10.1016/S2352-3026(15)00150-7

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

2015

Journal Article

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

Kurtz, David M., Green, Michael R., Bratman, Scott V., Scherer, Florian, Liu, Chih Long, Kunder, Christian A., Takahashi, Kazuhiro, Glover, Cynthia, Keane, Colm, Kihira, Shingo, Visser, Brendan, Callahan, Jason, Kong, Katherine A., Faham, Malek, Corbelli, Karen S., Miklos, David, Advani, Ranjana H., Levy, Ronald, Hicks, Rodney J., Hertzberg, Mark, Ohgami, Robert S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125 (24), 3679-3687. doi: 10.1182/blood-2015-03-635169

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

2015

Journal Article

Prehospital use of magnesium sulfate as neuroprotection in acute stroke

Saver, Jeffrey L., Starkman, Sidney, Eckstein, Marc, Stratton, Samuel J., Pratt, Franklin D., Hamilton, Scott, Conwit, Robin, Liebeskind, David S., Sung, Gene, Kramer, Ian, Moreau, Gary, Goldweber, Robert, Sanossian, Nerses, Ali, A., Andruss, K., Beck, B., Chin, S., Conneen, D., Copeland, D., Crisan, A., Gale, L., Ganguly, G., Gonzalez, J. E., Helfgott, P., Hovanessian, H., Jarema, E., Liu, M., Martin, M. L., Meyer, G. ... Sacco, R. (2015). Prehospital use of magnesium sulfate as neuroprotection in acute stroke. New England Journal of Medicine, 372 (6), 528-536. doi: 10.1056/NEJMoa1408827

Prehospital use of magnesium sulfate as neuroprotection in acute stroke

2015

Conference Publication

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Lecao K.-A., Keane C., Han E., Talaulikar D. and Gandhi M. (2015). Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios. Scientific Stream at Big Data in Health Analytics 2015, BigData 2015, Sydney; Australia, October 20, 2015-October 21, 2015. Aachen, Germany: Rheinisch-Westfaelische Technische Hochschule Aachen.

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

2015

Conference Publication

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology.

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

Current funding

  • 2024 - 2029
    BrainCAR19 Study- Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2022 - 2027
    An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas -- 2: TREBL-2 (Stream 6)
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2021 - 2026
    Investigation of Immune evasion in relapsed lymphoma (RADD Trial) (Victorian Cancer Agency Translational Research Project administered by La Trobe University)
    Olivia Newton-John Cancer Research Institute
    Open grant
  • 2021 - 2025
    Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
    NHMRC MRFF Investigator Grant
    Open grant
  • 2019 - 2026
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2021 - 2024
    ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma
    Australasian Leukaemia & Lymphoma Group
    Open grant
  • 2021 - 2025
    Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma (MRFF RCRDUN administered by La Trobe University)
    La Trobe University
    Open grant
  • 2020 - 2023
    Novel immune based approaches to improve survival for patients with Primary Central Nervous Lymphoma
    Queensland Advancing Clinical Research Fellowship
    Open grant
  • 2019 - 2020
    Investigation of the key immuno-genetic drivers of Primary Central Nervous System Lymphoma that occurs in patients with HIV infection
    Cancer Australia
    Open grant
  • 2017 - 2020
    Investigation of unique immune microenvironment of Primary CNS Lymphoma
    NHMRC Early Career Fellowships
    Open grant
  • 2017 - 2019
    The prognostic utility of the tumour microenvironment in Non-Hodgkin's Lymphoma
    Celgene Pty Ltd
    Open grant
  • 2016 - 2017
    Does lymphoma avoid immune destruction by inducing T-cell tolerance?
    Cancer Council Queensland
    Open grant
  • 2015 - 2018
    A correlative laboratory study of primary CNS lymphoma
    Research Donation Generic
    Open grant
  • 2015 - 2018
    Net tumoral immunity and its impact on outcome in lymphoma
    The Leukaemia Foundation of Australia Limited
    Open grant

Availability

Associate Professor Colm Keane is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au